Table 3.

PDAC patient distributions according to the different EMT phenotypes of CTCs and clinic-pathological features after palliative chemotherapy.

		Epithelial CTC 8/19 (42.1%)	Hybrid CTC 7/19 (36.8%)	Mesenchymal CTC 4/19 (21.1%)
TNM stage	I		1/19 (5.3%)
	II	3/19 (15.8%)	2/19 (10.1%)	1/19 (5.3%)
	III	4/19 (21.1%)	3/19 (15.8%)
	IV	1/19 (5.3%)	1/19 (5.3%)	3/19 (15.8%)
Lymph node metastasis	Negative	3/19 (15.8%)	1/19 (5.3%)
	Positive	6/19 (31.6%)	7/19 (36.9%)	2/19 (10.1%)	*
Distant metastasis	Negative	4/19 (21.1%)	1/19 (5.3%)	2/19 (10.1%)
	Positive	4/19 (21.1%)	6/19 (31.6%)	2/19 (10.1%)	*
Metastasis sites	Liver	3/12 (25%)	4/12 (33.3%)
	Other	1/12 (8.3%)	2/12 (16.7%)	2/12 (16.7%)
CTC number	High	6/19 (31.6%)	5/19 (26.3%)	4/19 (21.1%)
	Low	2/19 (10.1%)	2/19 (10.1%)
CTC cluster	Yes	6/19 (31.6%)	5/19 (26.3%)	4/19 (21.1%)
	No	2/19 (10.1%)	2/19 (10.1%)

^*p < 0.01.